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INTRODUCTION
Pheochromocytomas (PCCs) are uncommon, catecholamine-
producing, neuroendocrine tumors that mainly arise from 
chromaffin cells in adrenal gland. Usually, PCCs are benign 
tumors, but some have clinically malignant characteristics. 
The prevalence of malignancy is commonly cited at about 10%, 
but other estimates suggest rates of between 5–26%, depend-
ing on how malignancy is defined [1]. Malignant PCCs are 
able to metastasize to other organs in absence of chromaffin 
cells. Malignant PCC often metastasize to the skeletal system, 
liver, lung, and regional lymph nodes [2]. Cerebral metastases 
in PCC are exceptionally rare. In this report, we present the 
unique case of brain metastasis from adrenal PCC, which has 
been managed by surgical resection and radiotherapy.
CASE REPORT
A 52-year-old man admitted on January 2017 with com-
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Pheochromocytoma (PCC) is a neuroendocrine tumor that mainly arises from the medulla of the adre-
nal gland. Some PCCs become malignant and metastasize to other organs. For example, it typically 
involves skeletal system, liver, lung, and regional lymph nodes. However, only a few cases of PCC with 
brain metastasis have been reported worldwide. We report a case of metastatic brain tumor from PCC 
in South Korea in 2016. A 52-year-old man presented with headache, dizziness and motor aphasia. 
He had a medical history of PCC with multi-organ metastasis, previously underwent several opera-
tions, and was treated with chemotherapy and radiotherapy. Brain MRIs showed a brain tumor on the 
left parietal lobe. Postoperative pathology confirmed that the metastatic brain tumor derived from ma-
lignant PCC. This is the first report PCC with brain metastasis in South Korea.
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plaints of headache, dizziness and motor aphasia. On October 
2015, he complained of left hip pain, and was diagnosed with 
a left adrenal cortical adenoma on abdomino-pelvic CT when 
examined at a local medical center. However, he had no surgi-
cal treatment, and follow-up CT showed a huge, left adrenal 
mass compressing spleen, pancreas and thrombus in inferior 
vena cava (IVC), right common iliac vein. The patient under-
went left adrenalectomy, left nephrectomy, IVC reconstruc-
tion, thrombectomy, and distal subtotal pancreatectomy with 
splenectomy on January 2016. Thereafter, he was treated with 
metaiodobenzylguanidine therapy and underwent excision of 
the retroperitoneal cancer on June 2016. Despite 2 times of op-
erations and radiotherapy sections, follow-up CT showed pro-
gressive disease, and he was treated with additional 3 cycles of 
combination chemotherapy with cyclophosphamide, vincris-
tine and dacarbazine (CVD) and 2 cycles of combination che-
motherapy with etoposide, ifosfamide and cisplatin (VIP-STS), 
but the tumor size did not reduce. In addition, the patient re-
ceived mediastinal and subdiaphragm mass excision and dia-
phragm repair. The patient was scheduled to undergo CT fol-
low-up and positron emission tomography-CT to evaluate 
cancer progression. However, the patient had symptoms of 
headache, dizziness and motor aphasia, and brain MRI showed 
multiple (more than 10) enhancing masses in the bilateral cere-
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bral hemisphere and right pons. The largest one measured 5.7 
cm, and featured a cystic mass with hemorrhagic components 
and perilesional edema in left parietal lobe, compressing left 
lateral ventricle inferiorly, and causing midline shift to the 
right. Some lesions showed hemorrhagic change (Fig. 1). We 
performed a left parietal craniotomy with gross total tumor 
removal by transcortical approach on February 2, 2017. 
While the patient was anesthetized, we performed a left pari-
eto-occipital craniotomy and corticectomy by using a naviga-
tion device. Once the tumor margin was exposed and dissect-
ed with a CUSA and microdissector, the tumor was removed. 
On gross examination, a 5.8 cm sized hypervascular tumor 
was observed inside of the ventricle trigone when it was 
opened. PCC was diagnosed by frozen biopsy samples, and 
later confirming the diagnosis by examining tissue pathology. 
Postoperative MRI showed total removal of the largest mass 
in parietal area and a slightly improved midline shift. The size 
of other multiple metastatic lesions in the bilateral cerebral 
hemisphere, with or without hemorrhage, and the size of the 
right pons did not change (Fig. 2). However, the patient dem-
onstrated right hemianopsia during the postoperative visual 
field test (Humphrey test). On day 7, the patient experienced 
severe headaches and visual field was blurred and we took 
emergent brain CT and revealed intracerebral hemorrhage 
(ICH) on right occipital area. Navigation guided ICH catheter 
insertion was performed immediately in the operating room. 
On day 10, ICH catheter was removed and discharged. Post-
operative whole brain radiotherapy was scheduled in order to 
remove any residual metastatic lesions. Total of 3,000 cGy (300 
cGy/fx×10 fx) radiotherapy was performed. Thereafter, fol-
Fig. 1. Postcontrast axial T1-weighted magnetic resonance finding of intracranial metastatic PCC at preoperation. A: Largest one measur-
ing 5.7 cm solid and cystic mass with hemorrhagic components and perilesional edema in left parietal lobe, compressing left lateral ventri-
cle inferiorly. B and C: Multiple enhancing masses in bilateral cerebral hemisphere and right pons.
Fig. 2. Postcontrast axial T1-weighted magnetic resonance finding of intracranial metastatic PCC at postoperation. A: Postoperative acute 
ischemic change and hemorrhage along the resection margin left parietal, temporal and frontal lobe. Slightly improved midline shift. B and C: 
No change in size of other multiple metastatic lesions with or without hemorrhage in the bilateral cerebral hemisphere and right pons. 
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malignant PCC with brain metastasis case reported in 2010, 
deletion of chromosome 18q is a unique characteristic com-
pared to other malignant PCC cases. Histopathological mor-
phology of PCC is a Zellballen growth pattern, separated by 
delicate, fibrovascular stroma. However, in some cases of PCC, 
the Zellballen pattern is not seen, and a diffuse growth type 
pattern is detected. In our cases, hematoxylin and eosin stain 
displayed atypical cells with eosinophilic cytoplasm and hy-
perchromatic nuclei surrounded by sustentacular cells and dif-
fuse pattern (Fig. 3A, B). Staining for synaptophysin (neuroen-
docrine marker) is markedly positive for tumor cells and the 
surrounding sustentacular cells are positive for S-100 (Fig. 3C, 
D). Additionally, for differential diagnosis with a primary glial 
tumor, Oligo-2 immunohistochemical analysis was performed, 
and the tumor was found to be negative for Oligo-2 (Fig. 3E). 
These histopathological findings supported the diagnosis of 
PCC. Usually, PCCs release catecholamines causing hyperten-
sion, palpitation and sweating. As a result, blood or 24-h urine 
has elevated levels of catecholamines (metanephrine, dopamine, 
and vanillylmandelic acid). However, our patient had no typi-
cal cardiac symptoms and maintained catecholamine levels 
within the normal range during the course of the case study. In 
some rare cases, PCCs do not synthesize or release any cate-
cholamines (non-functional tumors). Tumors due to SDH B 
gene mutations are often subclinical, poorly differentiated, con-
tain low amounts of catecholamines, and are usually malignant 
at diagnosis [10]. Postoperative whole brain radiotherapy is 
low-up brain MRI showed the partial decrease in size of mul-
tiple metastatic lesions, and no other newly appearing lesion. 
Unfortunately, the patient’s intraabdominal cancer progressed 
further, and he expired. This case report was performed with 
informed consent according to protocols approved by Institu-
tional Review Boards of Severance Hospital (4-2018-0790).
DISCUSSION
PCCs are usually benign tumors arising from chromaffin 
cells found mainly of the adrenal gland that may sometimes 
become malignant [3]. To establish malignancy in PCC re-
quires evidence of metastases to nonchromaffin sites (not in 
adrenal medulla or sympathetic nervous ganglia). These sites 
include the skeletal system, liver, lung, and regional lymph 
nodes [4]. The 5-year survival rate in metastatic PCC is esti-
mated at <50% [3]. Cerebral metastases in PCC are exception-
ally rare [5-8]. According to literature, a total of 3 cases have 
been reported so far. The first reported case was of a 49-year-
old man in 1992 in France. Thereafter, a 31-year-old woman 
and a 53-year-old man were reported in 2001 and 2010, respec-
tively [6,8,9]. Prior to this, there has been no case report of PCC 
with brain metastasis from Korea. The literature suggests that 
genetic alteration may be associated with cerebral metastasis 
in malignant PCCs. In certain patient groups with a mutation 
in the succinate dehydrogenase (SDH) B gene, malignancy is 
reported to occur in as many as 83% of patients [9]. In the 
Fig. 3. Tumor histopathology. A and B: Atypical cells with eosinophilic cytoplasm and hyperchromatic nuclei (hematoxylin and eosin staining, 
original magnification ×400 and ×200). C: Positive for synaptophysin (immunostain, neuroendocrine marker, original magnification ×100). D: 
Positive for S-100 (immunostain, suscentacular cell marker, original magnification ×200). E: Negative for Oligo-2 (Immunostain, glial cell tumor 
marker, original magnification ×100).
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used to treat PCC with brain metastasis. However, because of 
the rarity of these tumors, the prognosis of the disease and ef-
ficacy of radiotherapy is not clear.
Brain metastases from PCC are rarely reported. To the best 
of our knowledge, this is the first case in the literature, where 
a brain metastasis from PCC has been reported in Korea. And 
the possibility of metastasis to brain has not been excluded. 
Therefore, patients with malignant PCC and have neurologi-
cal symptoms are needed to support the findings of the brain 
imaging study.
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